Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This investigator-initiated, prospective, single-arm, phase I dose-escalation trial aims to evaluate the safety and tolerability of anti-CD19/CD22 dual-target cord blood-derived CAR-T cells in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia who have failed prior therapies, with the goal of reducing antigen-escape relapse and overcoming poor autologous T-cell fitness through the use of universally available umbilical cord blood T cells.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent lub jego opiekun prawny wyraża zgodę na udział w badaniu.
- •Wiek od 18 do 75 lat.
- •Zdiagnozowana nawrotowa lub oporna białaczka limfoblastyczna B.
- •Komórki białaczkowe wykazują obecność markerów CD19 i/lub CD22.
- •Ogólny stan zdrowia pozwalający na udział w badaniu (niezbyt ciężki).
✗ Disqualifies
- •Aktywna choroba przeszczep przeciwko gospodarzowi (GVHD) lub choroby autoimmunologiczne.
- •Przyjmowanie leków sterydowych w dużych dawkach w ciągu ostatnich 7 dni.
- •Niekontrolowane wysokie ciśnienie krwi.
- •Poważne choroby serca.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Trial contact
Weiyang Liu
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/25/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.